Literature DB >> 20874733

Genetic and morphologic features for melanoma classification.

Sigrid M C Broekaert1, Ritu Roy, Ichiro Okamoto, Joost van den Oord, Jürgen Bauer, Claus Garbe, Raymond L Barnhill, Klaus J Busam, Alistair J Cochran, Martin G Cook, David E Elder, Stanley W McCarthy, Martin C Mihm, Dirk Schadendorf, Richard A Scolyer, Alan Spatz, Boris C Bastian.   

Abstract

Melanoma is comprised of biologically distinct subtypes. The defining clinical, histomorphologic, and molecular features are not fully established. This study sought to validate the association between genetic and histomorphologic features previously described and to determine their reproducibility and association with important clinical variables. Detailed clinical and histomorphologic features of 365 primary cutaneous melanomas were assessed by 11 pathologists and correlated with mutation status of BRAF and NRAS. There was substantial agreement in the quantitative assessment of histomorphologic features showing similar or better interobserver reproducibility than the established World Health Organization classification scheme. We confirmed that melanomas with BRAF mutations showed characteristic morphologic features (P < 0.0001) and metastasized more frequently to regional lymph nodes (P = 0.046). Importantly, melanomas without mutations were a heterogeneous group, with a subset having very similar clinical and morphological features as those with BRAF mutation raising the possibility that they are biologically related. Our study confirms an association between histomorphologic features, mutation status, and pattern of metastasis, providing criteria for a refined melanoma classification aimed at defining biologically homogeneous disease subgroups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874733      PMCID: PMC3107973          DOI: 10.1111/j.1755-148X.2010.00778.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  14 in total

1.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

2.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

3.  A new American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; M B Atkins; N Cascinelli; D G Coit; I D Fleming; A Houghton; J M Kirkwood; M F Mihm; D L Morton; D Reintgen; M I Ross; A Sober; S J Soong; J A Thompson; J F Thompson; J E Gershenwald; K M McMasters
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

4.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

5.  Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.

Authors:  B C Bastian; M Kashani-Sabet; H Hamm; T Godfrey; D H Moore; E B Bröcker; P E LeBoit; D Pinkel
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

6.  Melanoma molecular subtypes: unifying and paradoxical results.

Authors:  Nancy E Thomas; Peter A Kanetsky; Colin B Begg; Kathleen Conway; Marianne Berwick
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

7.  Determinants of BRAF mutations in primary melanomas.

Authors:  Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

8.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Authors:  Katarina Omholt; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

10.  Improving melanoma classification by integrating genetic and morphologic features.

Authors:  Amaya Viros; Jane Fridlyand; Juergen Bauer; Konstantin Lasithiotakis; Claus Garbe; Daniel Pinkel; Boris C Bastian
Journal:  PLoS Med       Date:  2008-06-03       Impact factor: 11.069

View more
  47 in total

1.  Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.

Authors:  Arata Tsutsumida; Akira Takahashi; Kenjiro Namikawa; Naoya Yamazaki; Hisashi Uhara; Yukiko Teramoto; Tatsuya Takenouchi; Satoshi Fukushima; Kenji Yokota; Jiro Uehara; Shigeto Matsushita; Yoshitsugu Shibayama; Naohito Hatta; Yuri Masui; Hiroshi Uchi; Yasuhiro Fujisawa; Dai Ogata
Journal:  Int J Clin Oncol       Date:  2016-01-13       Impact factor: 3.402

Review 2.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

3.  Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Authors:  Robert V Rawson; Peter A Johansson; Nicholas K Hayward; Nicola Waddell; Ann-Marie Patch; Serigne Lo; John V Pearson; John F Thompson; Graham J Mann; Richard A Scolyer; James S Wilmott
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

4.  Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms.

Authors:  Heidi V N Küsters-Vandevelde; Ilse A C H van Engen-van Grunsven; Sarah E Coupland; Sarah L Lake; Jos Rijntjes; Rolph Pfundt; Benno Küsters; Pieter Wesseling; Willeke A M Blokx; Patricia J T A Groenen
Journal:  Pathol Oncol Res       Date:  2014-10-15       Impact factor: 3.201

Review 5.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Authors:  Richard A Scolyer; Georgina V Long; John F Thompson
Journal:  Mol Oncol       Date:  2011-03-21       Impact factor: 6.603

Review 6.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

7.  Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Pamela A Groben; Eloise Parrish; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Lynn From; Klaus J Busam; Honglin Hao; Irene Orlow; Peter A Kanetsky; Li Luo; Anne S Reiner; Susan Paine; Jill S Frank; Jennifer I Bramson; Lorraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

Review 8.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.

Authors:  Holly S Greenwald; Erica B Friedman; Iman Osman
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

9.  Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.

Authors:  Marina Kvaskoff; David C Whiteman; Zhen Z Zhao; Grant W Montgomery; Nicholas G Martin; Nicholas K Hayward; David L Duffy
Journal:  Twin Res Hum Genet       Date:  2011-10       Impact factor: 1.587

10.  BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.

Authors:  Jillian M Silva; Christina Bulman; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-01-14       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.